BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Michalski JE, Kurche JS, Schwartz DA. From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic? Transl Res 2021:S1931-5244(21)00243-7. [PMID: 34547499 DOI: 10.1016/j.trsl.2021.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhong H, Zhou Y, Mei S, Tang R, Feng J, He Z, Xu Q, Xing S. Scars of COVID-19: A bibliometric analysis of post-COVID-19 fibrosis. Front Public Health 2022;10:967829. [DOI: 10.3389/fpubh.2022.967829] [Reference Citation Analysis]
2 Mokra D, Adamcakova J, Mokry J. Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG): A Time for a New Player in the Treatment of Respiratory Diseases? Antioxidants (Basel) 2022;11:1566. [PMID: 36009285 DOI: 10.3390/antiox11081566] [Reference Citation Analysis]
3 Doan LH, Chu L, Huang Z, Nguyen AT, Lee C, Huang C, Chang Y, Hsieh W, Nguyen TTH, Lin C, Su C, Chuang T, Lai J, Wang F, Yang C, Liu H, Ping Y, Huang CF. Virofree, an Herbal Medicine-Based Formula, Interrupts the Viral Infection of Delta and Omicron Variants of SARS-CoV-2. Front Pharmacol 2022;13:905197. [DOI: 10.3389/fphar.2022.905197] [Reference Citation Analysis]
4 Dempsey OJ. Half a billion cases of COVID-19 and counting: Are we facing a new lung fibrosis pandemic, and can we treat it? Journal of the Royal College of Physicians of Edinburgh 2022;52:90-2. [DOI: 10.1177/14782715221104857] [Reference Citation Analysis]
5 Ruggiero V, Aquino RP, Del Gaudio P, Campiglia P, Russo P. Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary sequelae after COVID-19 Infection. Pharmaceutics 2022;14:1135. [DOI: 10.3390/pharmaceutics14061135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang Z, Zhang Y, Yang R, Wang Y, Guo J, Sun R, Zhou Y, Su L, Ge Q, Feng Y. Landscape of Peripheral Blood Mononuclear Cells and Soluble Factors in Severe COVID-19 Patients With Pulmonary Fibrosis Development. Front Immunol 2022;13:831194. [PMID: 35558069 DOI: 10.3389/fimmu.2022.831194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hammad R, Kotb HG, Eldesoky GA, Mosaad AM, El-nasser AM, Abd El Hakam FE, Eldesoky NA, Mashaal A, Farhoud H. Utility of Monocyte Expression of HLA-DR versus T Lymphocyte Frequency in the Assessment of COVID-19 Outcome. IJGM 2022;Volume 15:5073-87. [DOI: 10.2147/ijgm.s359690] [Reference Citation Analysis]
8 Xiang M, Jing H, Wang C, Novakovic VA, Shi J. Persistent Lung Injury and Prothrombotic State in Long COVID. Front Immunol 2022;13:862522. [PMID: 35464473 DOI: 10.3389/fimmu.2022.862522] [Reference Citation Analysis]
9 Chiner-vives E, Cordovilla-pérez R, Rosa-carrillo DDL, García-clemente M, Izquierdo-alonso JL, Otero-candelera R, Llano LP, Sellares-torres J, Granda-orive JID. Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. Archivos de Bronconeumología 2022. [DOI: 10.1016/j.arbres.2022.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
10 Margaria JP, Moretta L, Alves-filho JC, Hirsch E. PI3K Signaling in Mechanisms and Treatments of Pulmonary Fibrosis Following Sepsis and Acute Lung Injury. Biomedicines 2022;10:756. [DOI: 10.3390/biomedicines10040756] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Bergantini L, Mainardi A, d’Alessandro M, Cameli P, Bennett D, Bargagli E, Sestini P. Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review. Front Pharmacol 2022;13:748931. [DOI: 10.3389/fphar.2022.748931] [Reference Citation Analysis]
12 Rossiello F, Jurk D, Passos JF, d’Adda di Fagagna F. Telomere dysfunction in ageing and age-related diseases. Nat Cell Biol. [DOI: 10.1038/s41556-022-00842-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]